New approach to prevent breast cancer by targeting a specific histamine receptor
Exploring new strategy for breast cancer immunoprevention by targeting histamine receptor H1
This study is looking at how a type of allergy medicine called H1-antihistamines might help boost the immune system's ability to fight breast cancer, especially for patients who have already used these medications during their treatment.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11035062 on NIH RePORTER |
What this research studies
This research investigates a novel strategy for preventing breast cancer by focusing on the histamine receptor H1. It aims to understand how high levels of histamine and H1 receptor expression in tumors affect immune responses in breast cancer patients. The study will explore the potential of H1-antihistamines to enhance the effectiveness of immunotherapy by improving the activity of immune cells that fight tumors. Patients who have previously taken H1-antihistamines during immunotherapy may see improved outcomes, suggesting a promising avenue for breast cancer prevention.
Who could benefit from this research
Good fit: Ideal candidates for this research are women at high risk for developing breast cancer, especially those with stage 0 or 1 breast cancer.
Not a fit: Patients who have already been diagnosed with advanced breast cancer or those not at risk for developing the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new prevention strategies for breast cancer, particularly for women at high risk.
How similar studies have performed: Previous studies have shown promising results with H1-antihistamines in improving outcomes for patients undergoing immunotherapy, indicating that this approach may be effective.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Xiao, Yi — University of Tx Md Anderson Can Ctr
- Study coordinator: Xiao, Yi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.